Epidermal growth factor receptor targeting in head and neck cancer: Have we been just skimming the surface?

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1381-1383

  Hansen, Aaron R ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUOROURACIL; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; DRUG HALF LIFE; DRUG INDICATION; EDITORIAL; GENE AMPLIFICATION; GENE DOSAGE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIGAND BINDING; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECURRENT CANCER; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; TAXOIDS;

EID: 84876074689     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.9220     Document Type: Editorial

References (23)

1. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579-3584, 1993 (Pubitemid 23229640)
2. Temam S, Kawaguchi H, El-Naggar AK, et al: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164-2170, 2007 (Pubitemid 46954638)
3. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002 (Pubitemid 36025259)
4. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
5. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
6. Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007 (Pubitemid 46954639)
7. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
8. Martins RG, Parvathaneni U, Bauman JE, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 31:1415-1421, 2013
9. Ang KK, Zhang QE, Rosenthal DI, et al: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:360s, 2011 (suppl 15; abstr 5500)
10. Le Tourneau C, Michiels S, Gan HK, et al: Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. J Clin Oncol 27:5965-5971, 2009
11. Argiris A, Ghebremichael M, Gilbert J, et al: Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 31:1405-1414, 2013
12. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
13. Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
14. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
15. Carter P: Improving the efficacy of antibody-based cancer therapies. Nature Reviews Cancer 1:118-129, 2001
16. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews Drug Discovery 2:296-313, 2003 (Pubitemid 37361688)
17. Huang S, Armstrong EA, Benavente S, et al: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355-5362, 2004 (Pubitemid 39006556)
18. Seiwert T, Fayette J, Cupissol D, et al: A randomized, open-label, phase II study of afatinib (bibw 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data. Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ, January 26-28, 2012 (abstr LBPV-10)
19. Abdul Razak AR, Soulières D, Laurie SA, et al: A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol [epub ahead of print on October 28, 2012]
20. Young NR, Liu J, Pierce C, et al: Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Molecular Oncology [epub ahead of print on November 14, 2012]
21. Pedrero JM, Carracedo DG, Pinto CM, et al: Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114:242-248, 2005 (Pubitemid 40194293)
22. Brana I, Siu LL: Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 10:161, 2012
23. Stransky N, Egloff AM, Tward AD, et al: The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160, 2011